Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia Innovators: Singapore's Inviragen In Race With Sinovac For HFMD Vaccine

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - Inviragen (Singapore) Pte Ltd is recruiting patients for its Phase I clinical trial in Singapore for its hand, foot and mouth disease vaccine INV21
Advertisement

Related Content

Inviragen Finds New Life For Shelved Japanese Encephalitis Vaccine At State-Owned VABIOTECH
WuXi Celebrates First $100 Million Quarter; Sinovac Reports 50% Revenue Increase; SciClone Not Worried About Zydaxin Cuts: China Earnings Round Up (Part 1)
WuXi Celebrates First $100 Million Quarter; Sinovac Reports 50% Revenue Increase; SciClone Not Worried About Zydaxin Cuts: China Earnings Round Up (Part 1)
Vaccine Upstart Inviragen Aims to Capture Dengue Market
Vaccine Upstart Inviragen Aims to Capture Dengue Market
As Asia Gets Richer, Singapore's EDB Turns Investments To Tech-enabled, Remote Monitoring Start-Ups
As Asia Gets Richer, Singapore's EDB Turns Investments To Tech-enabled, Remote Monitoring Start-Ups
Leading Chinese Vaccine Developer Sinovac Conducts Technical Exchanges With Gates Foundation On Rotavirus Vaccine
SingVax Merges With Inviragen To Raise $15 Million In Series-A Financing For Vaccines To Fight Infectious Disease
Advertisement
UsernamePublicRestriction

Register

SC078523

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel